abstract：:Pretreatment cytogenetics is an important parameter for risk stratification and therapy approach in acute lymphoblastic leukemia (ALL). However, in up to 30% of cases, chromosome banding analysis (CBA) fails or reveals a normal karyotype. To characterize the subset of ALL with normal karyotype or failed CBA, we perfor...

journal_title：Leukemia

authors： Mühlbacher V,Haferlach T,Kern W,Zenger M,Schnittger S,Haferlach C

更新日期：2016-02-01 00:00:00

abstract：:PTEN gene inactivation by mutation or deletion is common in pediatric T-cell acute lymphoblastic leukemia (T-ALL), but the impact on outcome is unclear, particularly in patients with NOTCH1/FBXW7 mutations. We screened samples from 145 patients treated on the MRC UKALL2003 trial for PTEN mutations using heteroduplex a...

journal_title：Leukemia

authors： Jenkinson S,Kirkwood AA,Goulden N,Vora A,Linch DC,Gale RE

更新日期：2016-01-01 00:00:00

abstract：:P38α/β has been described as a tumor-suppressor controlling cell cycle checkpoints and senescence in epithelial malignancies. However, p38α/β also regulates other cellular processes. Here, we describe a role of p38α/β as a regulator of acute lymphoblastic leukemia (ALL) proliferation and survival in experimental ALL m...

journal_title：Leukemia

authors： Alsadeq A,Strube S,Krause S,Carlet M,Jeremias I,Vokuhl C,Loges S,Aguirre-Ghiso JA,Trauzold A,Cario G,Stanulla M,Schrappe M,Schewe DM

更新日期：2015-12-01 00:00:00

abstract：:Acute myeloid leukemia (AML) with 11q23/MLL rearrangement (MLL-r AML) is allocated to the intermediate- or high-risk cytogenetic prognostic category depending on the MLL fusion partner. A more favorable outcome has been reported in patients receiving an allogeneic hematopoietic stem-cell transplantation (alloHSCT), bu...

journal_title：Leukemia

authors： Pigneux A,Labopin M,Maertens J,Cordonnier C,Volin L,Socié G,Blaise D,Craddock C,Milpied N,Bacher U,Malard F,Esteve J,Nagler A,Mohty M,Acute Leukemia Working Party EBMT.

更新日期：2015-12-01 00:00:00

abstract：:The added value of IKZF1 gene deletion (IKZF1(del)) as a stratifying criterion in B-cell precursor acute lymphoblastic leukemia (BCP-ALL) is still debated. We performed a comprehensive analysis of the impact of IKZF1(del) in a large cohort of children (n=1223) with BCR-ABL1-negative BCP-ALL treated in the EORTC-CLG tr...

journal_title：Leukemia

authors： Clappier E,Grardel N,Bakkus M,Rapion J,De Moerloose B,Kastner P,Caye A,Vivent J,Costa V,Ferster A,Lutz P,Mazingue F,Millot F,Plantaz D,Plat G,Plouvier E,Poirée M,Sirvent N,Uyttebroeck A,Yakouben K,Girard S,Dastu

更新日期：2015-11-01 00:00:00

abstract：:Imatinib is a highly effective therapy for chronic phase-chronic myeloid leukaemia (CP-CML) patients; however, responses to frontline imatinib are variable. The human organic cation transporter 1 (OCT1; SLC22A1) has been reported to be the main influx transporter involved in imatinib uptake into CML cells. Furthermore...

journal_title：Leukemia

authors： Watkins DB,Hughes TP,White DL

更新日期：2015-10-01 00:00:00

abstract：:Outcomes after unmanipulated haploidentical stem cell transplantation (Haplo) and after unrelated cord blood transplantation (UCBT) are encouraging and have become alternative options to treat patients with high-risk acute leukemia without human leukocyte antigen (HLA) matched donor. We compared outcomes after UCBT an...

journal_title：Leukemia

authors： Ruggeri A,Labopin M,Sanz G,Piemontese S,Arcese W,Bacigalupo A,Blaise D,Bosi A,Huang H,Karakasis D,Koc Y,Michallet M,Picardi A,Sanz J,Santarone S,Sengelov H,Sierra J,Vincent L,Volt F,Nagler A,Gluckman E,Ciceri F

更新日期：2015-09-01 00:00:00

abstract：:The B-cell receptor (BCR) and its immature form, the precursor-BCR (pre-BCR), have a central role in the control of B-cell development, which is dependent on a sequence of cell-fate decisions at specific antigen-independent checkpoints. Pre-BCR expression provides the first checkpoint, which controls differentiation o...

journal_title：Leukemia

authors： Eswaran J,Sinclair P,Heidenreich O,Irving J,Russell LJ,Hall A,Calado DP,Harrison CJ,Vormoor J

更新日期：2015-08-01 00:00:00

abstract：:Natural killer (NK) cells are cytotoxic lymphocytes that substantially contribute to the therapeutic benefit of antitumor antibodies like Rituximab, a crucial component in the treatment of B-cell malignancies. In chronic lymphocytic leukemia (CLL), the ability of NK cells to lyse the malignant cells and to mediate ant...

journal_title：Leukemia

authors： Wild J,Schmiedel BJ,Maurer A,Raab S,Prokop L,Stevanović S,Dörfel D,Schneider P,Salih HR

更新日期：2015-08-01 00:00:00

abstract：:The altered metabolism of cancer cells is a treasure trove to discover new antitumoral strategies. The gene (SLC7A5) encoding system L amino-acid transporter 1 (LAT1) is overexpressed in murine lymphoma cells generated via T-cell deletion of the pten tumor suppressor, and also in human T-cell acute lymphoblastic leuke...

journal_title：Leukemia

authors： Rosilio C,Nebout M,Imbert V,Griessinger E,Neffati Z,Benadiba J,Hagenbeek T,Spits H,Reverso J,Ambrosetti D,Michiels JF,Bailly-Maitre B,Endou H,Wempe MF,Peyron JF

更新日期：2015-06-01 00:00:00

abstract：:To characterise the genetics of splenic marginal zone lymphoma (SMZL), we performed whole exome sequencing of 16 cases and identified novel recurrent inactivating mutations in Kruppel-like factor 2 (KLF2), a gene whose deficiency was previously shown to cause splenic marginal zone hyperplasia in mice. KLF2 mutation wa...

journal_title：Leukemia

authors： Clipson A,Wang M,de Leval L,Ashton-Key M,Wotherspoon A,Vassiliou G,Bolli N,Grove C,Moody S,Escudero-Ibarz L,Gundem G,Brugger K,Xue X,Mi E,Bench A,Scott M,Liu H,Follows G,Robles EF,Martinez-Climent JA,Oscier D,Wa

更新日期：2015-05-01 00:00:00

abstract：:HOX homeobox proteins are key oncogenic drivers in hematopoietic malignancies. Here we demonstrate that HOXA1, HOXA6 and predominantly HOXA9 are able to induce the production of insulin-like growth factor 1 (Igf1). In chromatin immunoprecipitations, HOXA9 bound directly to the putative promoter and a DNase-hypersensit...

journal_title：Leukemia

authors： Steger J,Füller E,Garcia-Cuellar MP,Hetzner K,Slany RK

更新日期：2015-04-01 00:00:00

abstract：:FHL2, a member of the four and one half LIM domain protein family, is a critical transcriptional modulator. Here, we identify FHL2 as a critical regulator of hematopoietic stem cells (HSCs) that is essential for maintaining HSC self-renewal under regenerative stress. We find that Fhl2 loss has limited effects on hemat...

journal_title：Leukemia

authors： Hou Y,Wang X,Li L,Fan R,Chen J,Zhu T,Li W,Jiang Y,Mittal N,Wu W,Peace D,Qian Z

更新日期：2015-03-01 00:00:00

abstract：:In acute myeloid leukemia (AML), assessment of minimal residual disease (MRD) by flow cytometry (flow MRD) after induction and consolidation therapy has been shown to provide independent prognostic information. However, data on the value of earlier flow MRD assessment are lacking. Therefore, the value of flow MRD dete...

journal_title：Leukemia

authors： Köhnke T,Sauter D,Ringel K,Hoster E,Laubender RP,Hubmann M,Bohlander SK,Kakadia PM,Schneider S,Dufour A,Sauerland MC,Berdel WE,Büchner T,Wörmann B,Braess J,Hiddemann W,Spiekermann K,Subklewe M

更新日期：2015-02-01 00:00:00

abstract：:The efficacy of antibody-based immunotherapy is due to the activation of apoptosis, the engagement of antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity (CDC). We developed a novel strategy to enhance CDC using bispecific antibodies (bsAbs) that neutralize the C-regulators CD55 and CD59 to ...

journal_title：Leukemia

authors： Macor P,Secco E,Mezzaroba N,Zorzet S,Durigutto P,Gaiotto T,De Maso L,Biffi S,Garrovo C,Capolla S,Tripodo C,Gattei V,Marzari R,Tedesco F,Sblattero D

更新日期：2015-02-01 00:00:00

abstract：:Kinase inhibitors block proliferative signals in BCR-ABL1+ leukemic cells, but their capacity to induce apoptosis is poorly understood. Initial studies suggested that very brief exposure to kinase inhibitors was sufficient to induce apoptosis in chronic myeloid leukemia (CML) cells. However, flaws in this experimental...

journal_title：Leukemia

authors： Schafranek L,Nievergall E,Powell JA,Hiwase DK,Leclercq T,Hughes TP,White DL

更新日期：2015-01-01 00:00:00

abstract：:Perturbation in iron homeostasis is a hallmark of some hematologic diseases. Abnormal sideroblasts with accumulation of iron in the mitochondria are named ring sideroblasts (RS). RS is a cardinal feature of refractory anemia with RS (RARS) and RARS with marked thrombocytosis (RARS/-T). Mutations in SF3B1, a member of ...

journal_title：Leukemia

authors： Visconte V,Avishai N,Mahfouz R,Tabarroki A,Cowen J,Sharghi-Moshtaghin R,Hitomi M,Rogers HJ,Hasrouni E,Phillips J,Sekeres MA,Heuer AH,Saunthararajah Y,Barnard J,Tiu RV

更新日期：2015-01-01 00:00:00

abstract：:Mesenchymal stromal cells (MSCs) possess broad immunomodulatory capacities that are currently investigated for potential clinical application in treating autoimmune disorders. Third-party MSCs suppress alloantigen-induced proliferation of peripheral blood mononuclear cells providing the rationale for clinical use in g...

journal_title：Leukemia

authors： Malcherek G,Jin N,Hückelhoven AG,Mani J,Wang L,Gern U,Diehlmann A,Wuchter P,Schmitt A,Chen B,Ho AD,Schmitt M

更新日期：2014-12-01 00:00:00

abstract：:Identification of agents that target human leukemia stem cells is an important consideration for the development of new therapies. The present study demonstrates that rocaglamide and silvestrol, closely related natural products from the flavagline class of compounds, are able to preferentially kill functionally define...

journal_title：Leukemia

authors： Callahan KP,Minhajuddin M,Corbett C,Lagadinou ED,Rossi RM,Grose V,Balys MM,Pan L,Jacob S,Frontier A,Grever MR,Lucas DM,Kinghorn AD,Liesveld JL,Becker MW,Jordan CT

更新日期：2014-10-01 00:00:00

abstract：:Mesenchymal stromal cells (MSCs) are multipotent cells, which exhibit broad immunosuppressive activities. Moreover, they may be administered irrespectively of human leukocyte antigen (HLA) compatibility, without inducing life-threatening immunological reactions, as they express no HLA class II and limited HLA class I ...

journal_title：Leukemia

authors： Balan A,Lucchini G,Schmidt S,Schneider A,Tramsen L,Kuçi S,Meisel R,Bader P,Lehrnbecher T

更新日期：2014-10-01 00:00:00

abstract：:Treatment resistance in T-cell acute lymphoblastic leukemia (T-ALL) is associated with phosphatase and tensin homolog (PTEN) deletions and resultant phosphatidylinositol 3'-kinase (PI3K)-AKT pathway activation, as well as MYC overexpression, and these pathways repress mitochondrial apoptosis in established T-lymphobla...

journal_title：Leukemia

authors： Reynolds C,Roderick JE,LaBelle JL,Bird G,Mathieu R,Bodaar K,Colon D,Pyati U,Stevenson KE,Qi J,Harris M,Silverman LB,Sallan SE,Bradner JE,Neuberg DS,Look AT,Walensky LD,Kelliher MA,Gutierrez A

更新日期：2014-09-01 00:00:00

abstract：:In this report, a panel of European myeloma experts discuss the role of pomalidomide in the treatment of relapsed and refractory multiple myeloma (RRMM). Based on the available evidence, the combination of pomalidomide and low-dose dexamethasone is a well-tolerated and effective treatment option for patients with RRMM...

journal_title：Leukemia

authors： Dimopoulos MA,Leleu X,Palumbo A,Moreau P,Delforge M,Cavo M,Ludwig H,Morgan GJ,Davies FE,Sonneveld P,Schey SA,Zweegman S,Hansson M,Weisel K,Mateos MV,Facon T,Miguel JF

更新日期：2014-08-01 00:00:00

abstract：:Synergistic molecular vulnerabilities enhancing hypomethylating agents in myeloid malignancies have remained elusive. RNA-interference drug modifier screens identified antiapoptotic BCL-2 family members as potent 5-Azacytidine-sensitizing targets. In further dissecting BCL-XL, BCL-2 and MCL-1 contribution to 5-Azacyti...

journal_title：Leukemia

authors： Bogenberger JM,Kornblau SM,Pierceall WE,Lena R,Chow D,Shi CX,Mantei J,Ahmann G,Gonzales IM,Choudhary A,Valdez R,Camoriano J,Fauble V,Tiedemann RE,Qiu YH,Coombes KR,Cardone M,Braggio E,Yin H,Azorsa DO,Mesa RA,Ste

更新日期：2014-08-01 00:00:00

abstract：:In this study, we compared immunoglobulin heavy-chain-gene-based minimal residual disease (MRD) detection by real-time quantitative PCR (RQ-PCR) and next-generation sequencing (NGS) to assess whether NGS could overcome some limitations of RQ-PCR and further increase sensitivity, specificity, accuracy and reproducibili...

journal_title：Leukemia

authors： Ladetto M,Brüggemann M,Monitillo L,Ferrero S,Pepin F,Drandi D,Barbero D,Palumbo A,Passera R,Boccadoro M,Ritgen M,Gökbuget N,Zheng J,Carlton V,Trautmann H,Faham M,Pott C

更新日期：2014-06-01 00:00:00

abstract：:Allogeneic stem cell transplantation (allo-SCT) has so far been the most effective immunotherapy for hematological malignancies. However, it is becoming increasingly clear that the immunotherapeutic concepts underlying allo-SCT as well as the traditional dissection of the immune system into innate and adaptive arms ne...

journal_title：Leukemia

authors： Scheper W,Gründer C,Straetemans T,Sebestyen Z,Kuball J

更新日期：2014-06-01 00:00:00

abstract：:Therapy for multiple myeloma (MM) has markedly changed in the past decade with the introduction of new drugs, but it is not clear whether the improvements have been sustained. We studied 1038 patients diagnosed between 2001 and 2010, grouping patients into two 5-year periods by diagnosis, 2001-2005 and 2006-2010. The ...

journal_title：Leukemia

authors： Kumar SK,Dispenzieri A,Lacy MQ,Gertz MA,Buadi FK,Pandey S,Kapoor P,Dingli D,Hayman SR,Leung N,Lust J,McCurdy A,Russell SJ,Zeldenrust SR,Kyle RA,Rajkumar SV

更新日期：2014-05-01 00:00:00

abstract：:Prevailing wisdom holds that hematopoietic stem cells (HSCs) are predominantly quiescent. Although HSC cycle status has long been the subject of scrutiny, virtually all marrow stem cell research has been based on studies of highly purified HSCs. Here we explored the cell cycle status of marrow stem cells in un-separat...

journal_title：Leukemia

authors： Goldberg LR,Dooner MS,Johnson KW,Papa EF,Pereira MG,Del Tatto M,Adler DM,Aliotta JM,Quesenberry PJ

更新日期：2014-04-01 00:00:00

abstract：:In this study, we determined the respective roles of RelA and RelB NF-κB subunits in Epstein-Barr virus (EBV)-transformed B cells. Using different EBV-immortalized B-cell models, we showed that only RelA activation increased both survival and cell growth. RelB activity was induced secondarily to RelA activation and re...

journal_title：Leukemia

authors： Chanut A,Duguet F,Marfak A,David A,Petit B,Parrens M,Durand-Panteix S,Boulin-Deveza M,Gachard N,Youlyouz-Marfak I,Bordessoule D,Feuillard J,Faumont N

更新日期：2014-04-01 00:00:00

abstract：:Hematopoiesis is orchestrated by interactions between hematopoietic stem/progenitor cells (HSPCs) and stromal cells within bone marrow (BM) niches. Side population (SP) functionality is a major characteristic of HSPCs related to quiescence and resistance to drugs and environmental stresses. At steady state, SP cells a...

journal_title：Leukemia

authors： Malfuson JV,Boutin L,Clay D,Thépenier C,Desterke C,Torossian F,Guerton B,Anginot A,de Revel T,Lataillade JJ,Le Bousse-Kerdilès MC

更新日期：2014-04-01 00:00:00

abstract：:Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a very rare disease that currently lacks genomic and genetic biomarkers to assist in its clinical management. We performed whole-exome sequencing (WES) of three BPDCN cases. Based on these data, we designed a resequencing approach to identify mutations in 38 sele...

journal_title：Leukemia

authors： Menezes J,Acquadro F,Wiseman M,Gómez-López G,Salgado RN,Talavera-Casañas JG,Buño I,Cervera JV,Montes-Moreno S,Hernández-Rivas JM,Ayala R,Calasanz MJ,Larrayoz MJ,Brichs LF,Gonzalez-Vicent M,Pisano DG,Piris MA,Álvarez S,

更新日期：2014-04-01 00:00:00

abstract：:Successful treatment results for MLL-rearranged Acute Lymphoblastic Leukemia (ALL) in infants remain difficult to achieve. Significantly contributing to therapy failure is poor response to glucocorticoids (GCs), like prednisone. Thus, overcoming resistance to these drugs may be a crucial step towards improving prognos...

journal_title：Leukemia

authors： Spijkers-Hagelstein JA,Pinhanços SS,Schneider P,Pieters R,Stam RW

更新日期：2014-04-01 00:00:00

abstract：:Single kinase-targeted cancer therapies often failed prolonged responses because cancer cells bypass through alternative routes. In this study, high-throughput kinomic and proteomic approaches enabled to identify aberrant activity profiles in mixed lineage leukemia (MLL)-rearranged acute myeloid leukemia (AML) that de...

journal_title：Leukemia

authors： Kampen KR,Ter Elst A,Mahmud H,Scherpen FJ,Diks SH,Peppelenbosch MP,de Haas V,Guryev V,de Bont ES

更新日期：2014-03-01 00:00:00

abstract：:Bruton agammaglobulinemia tyrosine kinase (BTK), a cytoplasmic protein tyrosine kinase, is a component of the B-cell receptor signaling pathway. Ibrutinib, a BTK inhibitor, has demonstrated a significant clinical activity against chronic lymphocytic leukemia (CLL) in early clinical trials. Understanding the molecular ...

journal_title：Leukemia

authors： Cheng S,Ma J,Guo A,Lu P,Leonard JP,Coleman M,Liu M,Buggy JJ,Furman RR,Wang YL

更新日期：2014-03-01 00:00:00

abstract：:We previously identified autoantibodies to the endocytic-associated protein Huntingtin-interacting protein 1-related (HIP1R) in diffuse large B-cell lymphoma (DLBCL) patients. HIP1R regulates internalization of cell surface receptors via endocytosis, a process relevant to many therapeutic strategies including CD20 tar...

journal_title：Leukemia

authors： Wong KK,Gascoyne DM,Brown PJ,Soilleux EJ,Snell C,Chen H,Lyne L,Lawrie CH,Gascoyne RD,Pedersen LM,Møller MB,Pulford K,Murphy D,Green TM,Banham AH

更新日期：2014-02-01 00:00:00

abstract：:Less-intense remission induction regimens for adults with newly diagnosed acute myeloid leukemia (AML) aim to reduce treatment-related mortality (TRM), here defined as death within 4 weeks after starting induction therapy. This assumes that TRM rates are similar to the 15-20% observed 20 years ago. Herein we test this...

journal_title：Leukemia

authors： Othus M,Kantarjian H,Petersdorf S,Ravandi F,Godwin J,Cortes J,Pierce S,Erba H,Faderl S,Appelbaum FR,Estey E

更新日期：2014-02-01 00:00:00

abstract：:Oncogenic mutations in components of the JAK/STAT pathway, including those in cytokine receptors and JAKs, lead to increased activity of downstream signaling and are frequently found in leukemia and other hematological disorders. Thus, small-molecule inhibitors of this pathway have been the focus of targeted therapy i...

journal_title：Leukemia

authors： Lo MC,Peterson LF,Yan M,Cong X,Hickman JH,Dekelver RC,Niewerth D,Zhang DE

更新日期：2013-12-01 00:00:00

abstract：:Small-molecule multi-targeted cyclin-dependent kinase (CDK) inhibitors (CDKIs) are of particular interest due to their potent antitumor activity independent of p53 gene alterations. P53 deletion is associated with a very poor prognosis in multiple myeloma (MM). In this regard, we tested the anti-MM activity of RGB-286...

journal_title：Leukemia

authors： Cirstea D,Hideshima T,Santo L,Eda H,Mishima Y,Nemani N,Hu Y,Mimura N,Cottini F,Gorgun G,Ohguchi H,Suzuki R,Loferer H,Munshi NC,Anderson KC,Raje N

更新日期：2013-12-01 00:00:00

abstract：:c-MYC (hereafter MYC) overexpression has been recognized in aggressive B-cell lymphomas and linked to adverse prognosis. MYC activation results in widespread repression of micro-RNA (miRNA) expression and associated with lymphoma aggressive progression. Our recent study identified a MYC-miRNA-EZH2 feed-forward loop li...

journal_title：Leukemia

authors： Zhao X,Lwin T,Zhang X,Huang A,Wang J,Marquez VE,Chen-Kiang S,Dalton WS,Sotomayor E,Tao J

更新日期：2013-12-01 00:00:00

abstract：:Reliable detection of JAK2-V617F is critical for accurate diagnosis of myeloproliferative neoplasms (MPNs); in addition, sensitive mutation-specific assays can be applied to monitor disease response. However, there has been no consistent approach to JAK2-V617F detection, with assays varying markedly in performance, af...

journal_title：Leukemia

authors： Jovanovic JV,Ivey A,Vannucchi AM,Lippert E,Oppliger Leibundgut E,Cassinat B,Pallisgaard N,Maroc N,Hermouet S,Nickless G,Guglielmelli P,van der Reijden BA,Jansen JH,Alpermann T,Schnittger S,Bench A,Tobal K,Wilkins B,Cu

更新日期：2013-10-01 00:00:00

abstract：:Peripheral arterial occlusive disease (PAOD) occurs in patients with chronic phase chronic myeloid leukemia (CML-CP) treated with tyrosine kinase inhibitors (TKIs). The risk of developing PAOD on TKI therapy is unknown and causality has not been established. Patients with CML-CP from three randomized phase III studies...

journal_title：Leukemia

authors： Giles FJ,Mauro MJ,Hong F,Ortmann CE,McNeill C,Woodman RC,Hochhaus A,le Coutre PD,Saglio G

更新日期：2013-06-01 00:00:00